Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$893.52 -0.6%	$812.09	$510.05 ▼ $934.62	$55.90B	0.47	308,359 shs	333,160 shs
BNTX BioNTech	$90.54 +1.1%	$94.55	$79.52 ▼ $124.00	$22.64B	1.32	1.05 million shs	1.13 million shs
MRNA Moderna	$49.91 +0.5%	$49.61	$22.28 ▼ $59.55	$19.70B	1.05	5.06 million shs	5.08 million shs
QGEN Qiagen	$37.07 -0.9%	$37.07	$32.53 ▼ $57.81	$7.71B	0.66	2.05 million shs	1.89 million shs
TECH Bio-Techne	$54.00 0.0%	$52.13	$43.19 ▼ $72.16	$8.46B	1.37	2.90 million shs	2.56 million shs

The 7 Hottest IPOs On Wall Street’s 2026 Watchlist

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	+4.26%	+6.73%	+10.60%	+28.34%	+56.35%
BNTX BioNTech	+3.93%	-0.06%	-4.40%	-1.81%	-15.10%
MRNA Moderna	+7.94%	-3.78%	-6.81%	-5.56%	+78.88%
QGEN Qiagen	+0.95%	-0.33%	+11.04%	-7.91%	-23.96%
TECH Bio-Techne	+2.90%	+1.58%	+13.92%	+6.23%	+4.81%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$893.52 -0.6%	$812.09	$510.05 ▼ $934.62	$55.90B	0.47	308,359 shs	333,160 shs
BNTX BioNTech	$90.54 +1.1%	$94.55	$79.52 ▼ $124.00	$22.64B	1.32	1.05 million shs	1.13 million shs
MRNA Moderna	$49.91 +0.5%	$49.61	$22.28 ▼ $59.55	$19.70B	1.05	5.06 million shs	5.08 million shs
QGEN Qiagen	$37.07 -0.9%	$37.07	$32.53 ▼ $57.81	$7.71B	0.66	2.05 million shs	1.89 million shs
TECH Bio-Techne	$54.00 0.0%	$52.13	$43.19 ▼ $72.16	$8.46B	1.37	2.90 million shs	2.56 million shs

The 7 Hottest IPOs On Wall Street’s 2026 Watchlist

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	+4.26%	+6.73%	+10.60%	+28.34%	+56.35%
BNTX BioNTech	+3.93%	-0.06%	-4.40%	-1.81%	-15.10%
MRNA Moderna	+7.94%	-3.78%	-6.81%	-5.56%	+78.88%
QGEN Qiagen	+0.95%	-0.33%	+11.04%	-7.91%	-23.96%
TECH Bio-Techne	+2.90%	+1.58%	+13.92%	+6.23%	+4.81%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARGX argenex	2.92	Moderate Buy	$1,019.50	14.10% Upside
BNTX BioNTech	2.74	Moderate Buy	$129.56	43.10% Upside
MRNA Moderna	1.83	Reduce	$36.60	-26.67% Downside
QGEN Qiagen	2.42	Hold	$44.98	21.34% Upside
TECH Bio-Techne	2.67	Moderate Buy	$65.15	20.66% Upside

Current Analyst Ratings Breakdown

Latest QGEN, BNTX, TECH, MRNA, and ARGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2026	TECH Bio-Techne	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$65.00
6/11/2026	ARGX argenex	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$1,000.00
6/11/2026	TECH Bio-Techne	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold	$65.00
6/8/2026	MRNA Moderna	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Underperform	$32.00 ➝ $34.00
6/8/2026	TECH Bio-Techne	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
6/5/2026	BNTX BioNTech	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Perform
6/4/2026	ARGX argenex	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$1,000.00
6/1/2026	ARGX argenex	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$1,260.00 ➝ $1,291.00
6/1/2026	BNTX BioNTech	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
5/29/2026	QGEN Qiagen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D+)
5/27/2026	BNTX BioNTech	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$117.00 ➝ $135.00

(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARGX argenex	$4.25B	13.08	$22.11 per share	40.42	$118.34 per share	7.55
BNTX BioNTech	$3.25B	7.05	$1.40 per share	64.53	$96.59 per share	0.94
MRNA Moderna	$1.94B	10.19	N/A	N/A	$22.14 per share	2.25
QGEN Qiagen	$2.09B	3.65	$3.41 per share	10.87	$17.89 per share	2.07
TECH Bio-Techne	$1.22B	6.93	$2.52 per share	21.47	$12.24 per share	4.41

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARGX argenex	$1.29B	$22.46	39.78	26.66	1.32	31.31%	44.37%	37.55%	7/23/2026 (Estimated)
BNTX BioNTech	-$1.29B	-$5.88	N/A	N/A	N/A	-44.39%	-5.30%	-4.62%	8/3/2026 (Estimated)
MRNA Moderna	-$2.82B	-$8.15	N/A	N/A	N/A	-143.55%	-26.64%	-19.32%	7/31/2026 (Estimated)
QGEN Qiagen	$424.88M	$1.91	19.36	14.04	3.68	19.16%	14.40%	8.40%	8/4/2026 (Estimated)
TECH Bio-Techne	$73.40M	$0.69	78.26	29.83	5.02	9.05%	13.57%	10.66%	8/5/2026 (Estimated)

Latest QGEN, BNTX, TECH, MRNA, and ARGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2026	Q1 2026	ARGX argenex	$5.74	$5.52	-$0.22	$5.52	$1.44 billion	$1.31 billion
5/7/2026	Q1 2026	QGEN Qiagen	$0.54	$0.54	N/A	$0.33	$496.15 million	$492.32 million
5/6/2026	Q3 2026	TECH Bio-Techne	$0.55	$0.53	-$0.02	$0.32	$316.11 million	$311.42 million
5/4/2026	Q1 2026	BNTX BioNTech	-$2.52	-$2.2570	+$0.2630	-$2.43	$207.42 million	$136.71 million
5/1/2026	Q1 2026	MRNA Moderna	-$3.02	-$3.40	-$0.38	-$3.40	$236.37 million	$389.00 million
3/31/2026	Q1 2026	ARGX argenex	N/A	$5.52	N/A	$5.52	N/A	$1.31 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARGX argenex	N/A	N/A	N/A	N/A	N/A
BNTX BioNTech	N/A	N/A	N/A	N/A	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
QGEN Qiagen	$0.26	0.70%	N/A	13.61%	N/A
TECH Bio-Techne	$0.32	0.59%	N/A	46.38%	N/A

Latest QGEN, BNTX, TECH, MRNA, and ARGX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/11/2026	QGEN Qiagen	annual	$0.35	1.04%	7/7/2026	7/7/2026	7/14/2026
5/6/2026	TECH Bio-Techne	quarterly	$0.08	0.72%	5/18/2026	5/18/2026	5/29/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARGX argenex	N/A	5.23	4.87
BNTX BioNTech	0.01	8.80	8.74
MRNA Moderna	0.08	2.41	2.35
QGEN Qiagen	0.49	3.21	2.57
TECH Bio-Techne	0.10	4.49	3.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARGX argenex	60.32%
BNTX BioNTech	15.52%
MRNA Moderna	75.33%
QGEN Qiagen	70.00%
TECH Bio-Techne	98.95%

Insider Ownership

Company	Insider Ownership
ARGX argenex	2.43%
BNTX BioNTech	19.20%
MRNA Moderna	10.80%
QGEN Qiagen	9.00%
TECH Bio-Techne	1.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARGX argenex	1,863	62.19 million	60.68 million	Optionable
BNTX BioNTech	7,807	252.88 million	204.33 million	Optionable
MRNA Moderna	4,700	396.79 million	353.93 million	Optionable
QGEN Qiagen	5,654	206.07 million	187.53 million	Optionable
TECH Bio-Techne	3,100	156.57 million	154.53 million	Optionable

BNTX, MRNA, ARGX, TECH, and QGEN Headlines

Recent News About These Companies

TD Cowen Sticks to Their Buy Rating for Bio-Techne (TECH)

June 12 at 2:58 PM | theglobeandmail.com

New Bispecific Antibody Characterization Workflow Might Change The Case For Investing In Bio-Techne (TECH)

June 8, 2026 | finance.yahoo.com

3 Reasons TECH is Risky and 1 Stock to Buy Instead

June 8, 2026 | uk.finance.yahoo.com

Brokerages Set Bio-Techne Corp (NASDAQ:TECH) Target Price at $65.92

June 8, 2026 | americanbankingnews.com

Bio-Techne, Refeyn Partner on Workflow for Bispecific Antibody, Biosimilar Characterization

June 7, 2026 | genengnews.comG

Why Is Techne (TECH) Up 4.5% Since Last Earnings Report?

June 5, 2026 | zacks.com

Bio‑Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization

June 4, 2026 | prnewswire.com

Are Wall Street analysts bullish on Bio-Techne stock?

May 25, 2026 | msn.com

2 Healthcare Stocks to Research Further and 1 We Find Risky

May 23, 2026 | finance.yahoo.com

Bio-Techne Corp. stock underperforms Thursday when compared to competitors despite daily gains

May 22, 2026 | marketwatch.com

CMB.TECH NV (CMBT) Q1 2026 Earnings Call Transcript

May 19, 2026 | seekingalpha.com

Baron Asset Fund Sold Bio-Techne Corporation (TECH) Due to Concerns Over Potential Impact of AI

May 14, 2026 | finance.yahoo.com

The 5 most interesting analyst questions from Bio-Techne’s Q1 earnings call

May 13, 2026 | msn.com

Bio-Techne Insider Move: Major Director Stock Sale Raises Eyebrows on Wall Street

May 12, 2026 | tipranks.com

Bio-Techne Corporation (TECH) Presents at Bank of America Global Healthcare Conference 2026 Transcript

May 12, 2026 | seekingalpha.com

Bio-Techne Corp TE1

May 12, 2026 | morningstar.comM

Analysts Have Conflicting Sentiments on These Healthcare Companies: BillionToOne, Inc. Class A (BLLN) and Bio-Techne (TECH)

May 11, 2026 | theglobeandmail.com

Why Bio-Techne (TECH) Is Up 5.9% After Profits Rose Despite Slightly Lower Sales – And What's Next

May 8, 2026 | finance.yahoo.com

Bio-Techne (TECH) Q3 2026 Earnings Transcript

May 8, 2026 | finance.yahoo.com

Bio-Techne expects Q4 organic growth approximately flat while targeting ~100 bps margin expansion

May 6, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BNTX, MRNA, ARGX, TECH, and QGEN Company Descriptions

argenex NASDAQ:ARGX

$893.52 -5.42 (-0.60%)

Closing price 04:00 PM Eastern

Extended Trading

$893.08 -0.43 (-0.05%)

As of 04:58 PM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

BioNTech NASDAQ:BNTX

$90.54 +1.00 (+1.12%)

Closing price 04:00 PM Eastern

Extended Trading

$90.56 +0.02 (+0.02%)

As of 06:39 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Moderna NASDAQ:MRNA

$49.91 +0.27 (+0.54%)

Closing price 04:00 PM Eastern

Extended Trading

$49.96 +0.05 (+0.10%)

As of 08:00 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Qiagen NYSE:QGEN

$37.07 -0.35 (-0.94%)

Closing price 03:59 PM Eastern

Extended Trading

$37.06 0.00 (-0.01%)

As of 04:10 PM Eastern

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

Bio-Techne NASDAQ:TECH

$54.00 -0.02 (-0.04%)

Closing price 04:00 PM Eastern

Extended Trading

$54.02 +0.02 (+0.04%)

As of 04:42 PM Eastern

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QGEN, BNTX, TECH, MRNA, and ARGX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QGEN, BNTX, TECH, MRNA, and ARGX Earnings

Compare Dividends

Latest QGEN, BNTX, TECH, MRNA, and ARGX Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BNTX, MRNA, ARGX, TECH, and QGEN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BNTX, MRNA, ARGX, TECH, and QGEN Company Descriptions

argenex NASDAQ:ARGX

BioNTech NASDAQ:BNTX

Moderna NASDAQ:MRNA

Qiagen NYSE:QGEN

Bio-Techne NASDAQ:TECH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools